secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001193125-24-252153
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio reports Q3 net loss of $41.2M, submits NDA for taletrectinib in ROS1+ NSCLC
--------------------------------------------------------------------------------

- Net loss of $41.2M ($0.15 per share) vs $19.6M ($0.09) in Q3 2023; cash of $549.1M at Sept 30.
- NDA for taletrectinib submitted to FDA for line-agnostic full approval in advanced ROS1+ NSCLC; potential launch mid-2025.
- Pooled Phase 2 data: 89% ORR in TKI-naïve patients, median DOR 44 months and PFS 46 months; low 7% discontinuation rate.
- Appointed Philippe Sauvage as CFO in October; David Hung appointed Chairman, Robert Bazemore lead independent director.
- R&D expenses $27.7M (up $9.2M YoY); G&A $19.6M (up $11.8M YoY) driven by AnHeart acquisition costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524252153/0001193125-24-252153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524252153/d826537d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-252153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer